Use of il-28 and il-29 to treat cancer and autoimmune disorders
AssigneeZymoGenetics, Inc.
InventorsSean Doyle, Kevin M. Klucher, Pallavur V. Sivakumar, Wayne R. Kindsvogel, Chung Chan
Life of this patent
Estimating the term…
Abstract
Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 and IL-29 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer and/or autoimmune therapeutics.
Claims12
A method of treating renal cell carcinoma in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a formulation comprising a polypeptide comprising amino acid residues 1-176 of SEQ ID NO:159 and a pharmaceutically acceptable vehicle.
A method of treating renal cell carcinoma in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a polypeptide comprising amino acid residues 1-176 of SEQ ID NO:159.
Dependencies are inferred from the claim text.